Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 27 entries
Sorted by: Best Match Show Resources per page
Self-reported Depressive Symptoms in Myasthenia Gravis.

Journal of clinical neuromuscular disease

Fisher J, Parkinson K, Kothari MJ.
PMID: 19078699
J Clin Neuromuscul Dis. 2003 Mar;4(3):105-8. doi: 10.1097/00131402-200303000-00001.

It is well known that patients with a chronic medical illness experience major depression at a higher rate than the general population. The purpose of this study was to determine the frequency of depression among patients with myasthenia gravis...

Cite
Fisher J, Parkinson K, Kothari MJ. Self-reported Depressive Symptoms in Myasthenia Gravis. J Clin Neuromuscul Dis. 2003;4(3):105-8doi: 10.1097/00131402-200303000-00001.
Fisher, J., Parkinson, K., & Kothari, M. J. (2003). Self-reported Depressive Symptoms in Myasthenia Gravis. Journal of clinical neuromuscular disease, 4(3), 105-8. https://doi.org/10.1097/00131402-200303000-00001
Fisher, Justin, et al. "Self-reported Depressive Symptoms in Myasthenia Gravis." Journal of clinical neuromuscular disease vol. 4,3 (2003): 105-8. doi: https://doi.org/10.1097/00131402-200303000-00001
Fisher J, Parkinson K, Kothari MJ. Self-reported Depressive Symptoms in Myasthenia Gravis. J Clin Neuromuscul Dis. 2003 Mar;4(3):105-8. doi: 10.1097/00131402-200303000-00001. PMID: 19078699.
Copy Download .nbib Format: NLM
Management of motor rehabilitation in individuals with muscular dystrophies. 1.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology

Lombardo ME, Carraro E, Sancricca C, Armando M, Catteruccia M, Mazzone E, Ricci G, Salamino F, Santorelli FM, Filosto M.
PMID: 34355124
Acta Myol. 2021 Jun 30;40(2):72-87. doi: 10.36185/2532-1900-046. eCollection 2021 Jun.

Muscular dystrophy (MD) is a group of neuromuscular diseases characterized by progressive muscle weakness due to various mutations in several genes involved in muscle structure and function. The age at onset, evolution and severity of the different forms of...

Cite
Lombardo ME, Carraro E, Sancricca C, et al. Management of motor rehabilitation in individuals with muscular dystrophies. 1. Acta Myol. 2021;40(2):72-87doi: 10.36185/2532-1900-046.
Lombardo, M. E., Carraro, E., Sancricca, C., Armando, M., Catteruccia, M., Mazzone, E., Ricci, G., Salamino, F., Santorelli, F. M., Filosto, M. (2021). Management of motor rehabilitation in individuals with muscular dystrophies. 1. Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology, 40(2), 72-87. https://doi.org/10.36185/2532-1900-046
Lombardo, Maria Elena, et al. "Management of motor rehabilitation in individuals with muscular dystrophies. 1." Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology vol. 40,2 (2021): 72-87. doi: https://doi.org/10.36185/2532-1900-046
Lombardo ME, Carraro E, Sancricca C, Armando M, Catteruccia M, Mazzone E, Ricci G, Salamino F, Santorelli FM, Filosto M. Management of motor rehabilitation in individuals with muscular dystrophies. 1. Acta Myol. 2021 Jun 30;40(2):72-87. doi: 10.36185/2532-1900-046. eCollection 2021 Jun. PMID: 34355124; PMCID: PMC8290512.
Copy Download .nbib Format: NLM
BMP/TGF-β signaling as a modulator of neurodegeneration in ALS.

Developmental dynamics : an official publication of the American Association of Anatomists

Russo K, Wharton KA.
PMID: 33745185
Dev Dyn. 2022 Jan;251(1):10-25. doi: 10.1002/dvdy.333. Epub 2021 Mar 29.

This commentary focuses on the emerging intersection between BMP/TGF-β signaling roles in nervous system function and the amyotrophic lateral sclerosis (ALS) disease state. Future research is critical to elucidate the molecular underpinnings of this intersection of the cellular processes...

Cite
Russo K, Wharton KA. BMP/TGF-β signaling as a modulator of neurodegeneration in ALS. Dev Dyn. 2021;251(1):10-25doi: 10.1002/dvdy.333.
Russo, K., & Wharton, K. A. (2022). BMP/TGF-β signaling as a modulator of neurodegeneration in ALS. Developmental dynamics : an official publication of the American Association of Anatomists, 251(1), 10-25. https://doi.org/10.1002/dvdy.333
Russo, Kathryn, and Wharton, Kristi A. "BMP/TGF-β signaling as a modulator of neurodegeneration in ALS." Developmental dynamics : an official publication of the American Association of Anatomists vol. 251,1 (2022): 10-25. doi: https://doi.org/10.1002/dvdy.333
Russo K, Wharton KA. BMP/TGF-β signaling as a modulator of neurodegeneration in ALS. Dev Dyn. 2022 Jan;251(1):10-25. doi: 10.1002/dvdy.333. Epub 2021 Mar 29. PMID: 33745185.
Copy Download .nbib Format: NLM
N-of-1 trial of salbutamol in hyperkalaemic periodic paralysis.

Journal of neurology, neurosurgery, and psychiatry

Stunnenberg BC, Merkus EC, Raaphorst J, Saris CG, Groenewoud H, Statland J, Weijma R, van Vlijmen B, Griggs R, van Engelen BGM, van der Wilt GJ.
PMID: 34112717
J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1352-1353. doi: 10.1136/jnnp-2021-326347. Epub 2021 Jun 10.

No abstract available.

Cite
Stunnenberg BC, Merkus EC, Raaphorst J, et al. N-of-1 trial of salbutamol in hyperkalaemic periodic paralysis. J Neurol Neurosurg Psychiatry. 2021;92(12):1352-1353doi: 10.1136/jnnp-2021-326347.
Stunnenberg, B. C., Merkus, E. C., Raaphorst, J., Saris, C. G., Groenewoud, H., Statland, J., Weijma, R., van Vlijmen, B., Griggs, R., van Engelen, B. G. M., & van der Wilt, G. J. (2021). N-of-1 trial of salbutamol in hyperkalaemic periodic paralysis. Journal of neurology, neurosurgery, and psychiatry, 92(12), 1352-1353. https://doi.org/10.1136/jnnp-2021-326347
Stunnenberg, Bas C, et al. "N-of-1 trial of salbutamol in hyperkalaemic periodic paralysis." Journal of neurology, neurosurgery, and psychiatry vol. 92,12 (2021): 1352-1353. doi: https://doi.org/10.1136/jnnp-2021-326347
Stunnenberg BC, Merkus EC, Raaphorst J, Saris CG, Groenewoud H, Statland J, Weijma R, van Vlijmen B, Griggs R, van Engelen BGM, van der Wilt GJ. N-of-1 trial of salbutamol in hyperkalaemic periodic paralysis. J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1352-1353. doi: 10.1136/jnnp-2021-326347. Epub 2021 Jun 10. PMID: 34112717.
Copy Download .nbib Format: NLM
TDP-43 stabilizes G3BP1 mRNA: relevance to amyotrophic lateral sclerosis/frontotemporal dementia.

Brain : a journal of neurology

Sidibé H, Khalfallah Y, Xiao S, Gómez NB, Fakim H, Tank EMH, Di Tomasso G, Bareke E, Aulas A, McKeever PM, Melamed Z, Destroimaisons L, Deshaies JE, Zinman L, Parker JA, Legault P, Tétreault M, Barmada SJ, Robertson J, Vande Velde C.
PMID: 34115105
Brain. 2021 Dec 16;144(11):3461-3476. doi: 10.1093/brain/awab217.

TDP-43 nuclear depletion and concurrent cytoplasmic accumulation in vulnerable neurons is a hallmark feature of progressive neurodegenerative proteinopathies such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Cellular stress signalling and stress granule dynamics are now recognized to...

Cite
Sidibé H, Khalfallah Y, Xiao S, et al. TDP-43 stabilizes G3BP1 mRNA: relevance to amyotrophic lateral sclerosis/frontotemporal dementia. Brain. 2021;144(11):3461-3476doi: 10.1093/brain/awab217.
Sidibé, H., Khalfallah, Y., Xiao, S., Gómez, N. B., Fakim, H., Tank, E. M. H., Di Tomasso, G., Bareke, E., Aulas, A., McKeever, P. M., Melamed, Z., Destroimaisons, L., Deshaies, J. E., Zinman, L., Parker, J. A., Legault, P., Tétreault, M., Barmada, S. J., Robertson, J., & Vande Velde, C. (2021). TDP-43 stabilizes G3BP1 mRNA: relevance to amyotrophic lateral sclerosis/frontotemporal dementia. Brain : a journal of neurology, 144(11), 3461-3476. https://doi.org/10.1093/brain/awab217
Sidibé, Hadjara, et al. "TDP-43 stabilizes G3BP1 mRNA: relevance to amyotrophic lateral sclerosis/frontotemporal dementia." Brain : a journal of neurology vol. 144,11 (2021): 3461-3476. doi: https://doi.org/10.1093/brain/awab217
Sidibé H, Khalfallah Y, Xiao S, Gómez NB, Fakim H, Tank EMH, Di Tomasso G, Bareke E, Aulas A, McKeever PM, Melamed Z, Destroimaisons L, Deshaies JE, Zinman L, Parker JA, Legault P, Tétreault M, Barmada SJ, Robertson J, Vande Velde C. TDP-43 stabilizes G3BP1 mRNA: relevance to amyotrophic lateral sclerosis/frontotemporal dementia. Brain. 2021 Dec 16;144(11):3461-3476. doi: 10.1093/brain/awab217. PMID: 34115105; PMCID: PMC8677511.
Copy Download .nbib Format: NLM
Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion.

Biomedicine hub

Horgan D, Metspalu A, Ouillade MC, Athanasiou D, Pasi J, Adjali O, Harrison P, Hermans C, Codacci-Pisanelli G, Koeva J, Szucs T, Cursaru V, Belina I, Bernini C, Zhuang S, McMahon S, Toncheva D, Thum T.
PMID: 33987187
Biomed Hub. 2020 Dec 03;5(3):130-152. doi: 10.1159/000511678. eCollection 2020.

Recent advances in biomedicine are opening the door to new approaches, and treatment and prevention are being transformed by novel medicines based on genetic engineering, innovative cell-based therapies and tissue-engineered products, and combinations of a medical device with embedded...

Cite
Horgan D, Metspalu A, Ouillade MC, et al. Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion. Biomed Hub. 2020;5(3):130-152doi: 10.1159/000511678.
Horgan, D., Metspalu, A., Ouillade, M. C., Athanasiou, D., Pasi, J., Adjali, O., Harrison, P., Hermans, C., Codacci-Pisanelli, G., Koeva, J., Szucs, T., Cursaru, V., Belina, I., Bernini, C., Zhuang, S., McMahon, S., Toncheva, D., & Thum, T. (2020). Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion. Biomedicine hub, 5(3), 130-152. https://doi.org/10.1159/000511678
Horgan, Denis, et al. "Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion." Biomedicine hub vol. 5,3 (2020): 130-152. doi: https://doi.org/10.1159/000511678
Horgan D, Metspalu A, Ouillade MC, Athanasiou D, Pasi J, Adjali O, Harrison P, Hermans C, Codacci-Pisanelli G, Koeva J, Szucs T, Cursaru V, Belina I, Bernini C, Zhuang S, McMahon S, Toncheva D, Thum T. Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion. Biomed Hub. 2020 Dec 03;5(3):130-152. doi: 10.1159/000511678. eCollection 2020. PMID: 33987187; PMCID: PMC8101061.
Copy Download .nbib Format: NLM
Computational modelling of stem cell-niche interactions facilitates discovery of strategies to enhance tissue regeneration and counteract ageing.

The FEBS journal

Potapov I, García-Prat L, Ravichandran S, Muñoz-Cánoves P, Del Sol A.
PMID: 33752266
FEBS J. 2021 Mar 22; doi: 10.1111/febs.15832. Epub 2021 Mar 22.

The stem cell niche is a specialized microenvironment for stem cells in an adult tissue. The niche provides cues for the maintenance and regulation of stem cell activities and thus presents a target for potential rejuvenating strategies. García-Prat et...

Cite
Potapov I, García-Prat L, Ravichandran S, et al. Computational modelling of stem cell-niche interactions facilitates discovery of strategies to enhance tissue regeneration and counteract ageing. FEBS J. 2021;doi: 10.1111/febs.15832.
Potapov, I., García-Prat, L., Ravichandran, S., Muñoz-Cánoves, P., & Del Sol, A. (2021). Computational modelling of stem cell-niche interactions facilitates discovery of strategies to enhance tissue regeneration and counteract ageing. The FEBS journal, . https://doi.org/10.1111/febs.15832
Potapov, Ilya, et al. "Computational modelling of stem cell-niche interactions facilitates discovery of strategies to enhance tissue regeneration and counteract ageing." The FEBS journal vol. (2021). doi: https://doi.org/10.1111/febs.15832
Potapov I, García-Prat L, Ravichandran S, Muñoz-Cánoves P, Del Sol A. Computational modelling of stem cell-niche interactions facilitates discovery of strategies to enhance tissue regeneration and counteract ageing. FEBS J. 2021 Mar 22; doi: 10.1111/febs.15832. Epub 2021 Mar 22. PMID: 33752266.
Copy Download .nbib Format: NLM
A multimodal dataset for authoring and editing multimedia content: The MAMEM project.

Data in brief

Nikolopoulos S, Petrantonakis PC, Georgiadis K, Kalaganis F, Liaros G, Lazarou I, Adam K, Papazoglou-Chalikias A, Chatzilari E, Oikonomou VP, Kumar C, Menges R, Staab S, Müller D, Sengupta K, Bostantjopoulou S, Katsarou Z, Zeilig G, Plotnik M, Gotlieb A, Kizoni R, Fountoukidou S, Ham J, Athanasiou D, Mariakaki A, Comanducci D, Sabatini E, Nistico W, Plank M, Kompatsiaris I.
PMID: 29204464
Data Brief. 2017 Nov 03;15:1048-1056. doi: 10.1016/j.dib.2017.10.072. eCollection 2017 Dec.

We present a dataset that combines multimodal biosignals and eye tracking information gathered under a human-computer interaction framework. The dataset was developed in the vein of the MAMEM project that aims to endow people with motor disabilities with the...

Cite
Nikolopoulos S, Petrantonakis PC, Georgiadis K, et al. A multimodal dataset for authoring and editing multimedia content: The MAMEM project. Data Brief. 2017;15:1048-1056doi: 10.1016/j.dib.2017.10.072.
Nikolopoulos, S., Petrantonakis, P. C., Georgiadis, K., Kalaganis, F., Liaros, G., Lazarou, I., Adam, K., Papazoglou-Chalikias, A., Chatzilari, E., Oikonomou, V. P., Kumar, C., Menges, R., Staab, S., Müller, D., Sengupta, K., Bostantjopoulou, S., Katsarou, Z., Zeilig, G., Plotnik, M., Gotlieb, A., Kizoni, R., Fountoukidou, S., Ham, J., Athanasiou, D., Mariakaki, A., Comanducci, D., Sabatini, E., Nistico, W., Plank, M., & Kompatsiaris, I. (2017). A multimodal dataset for authoring and editing multimedia content: The MAMEM project. Data in brief, 151048-1056. https://doi.org/10.1016/j.dib.2017.10.072
Nikolopoulos, Spiros, et al. "A multimodal dataset for authoring and editing multimedia content: The MAMEM project." Data in brief vol. 15 (2017): 1048-1056. doi: https://doi.org/10.1016/j.dib.2017.10.072
Nikolopoulos S, Petrantonakis PC, Georgiadis K, Kalaganis F, Liaros G, Lazarou I, Adam K, Papazoglou-Chalikias A, Chatzilari E, Oikonomou VP, Kumar C, Menges R, Staab S, Müller D, Sengupta K, Bostantjopoulou S, Katsarou Z, Zeilig G, Plotnik M, Gotlieb A, Kizoni R, Fountoukidou S, Ham J, Athanasiou D, Mariakaki A, Comanducci D, Sabatini E, Nistico W, Plank M, Kompatsiaris I. A multimodal dataset for authoring and editing multimedia content: The MAMEM project. Data Brief. 2017 Nov 03;15:1048-1056. doi: 10.1016/j.dib.2017.10.072. eCollection 2017 Dec. PMID: 29204464; PMCID: PMC5709300.
Copy Download .nbib Format: NLM
Therapy development for neuromuscular diseases: translating hope into promise.

Future neurology

Bertoni C.
PMID: 24273459
Future Neurol. 2013 Jul 01;8(4). doi: 10.2217/fnl.13.29.

The Second Muscular Dystrophy Association Scientific Meeting was held on 21-24 April 2013 in Washington (DC, USA). The meeting provided an opportunity for research scientists, clinicians, government agencies and industry experts to highlight and discuss different aspects of therapy...

Cite
Bertoni C. Therapy development for neuromuscular diseases: translating hope into promise. Future Neurol. 2013;8(4)doi: 10.2217/fnl.13.29.
Bertoni, C. (2013). Therapy development for neuromuscular diseases: translating hope into promise. Future neurology, 8(4), . https://doi.org/10.2217/fnl.13.29
Bertoni, Carmen. "Therapy development for neuromuscular diseases: translating hope into promise." Future neurology vol. 8,4 (2013). doi: https://doi.org/10.2217/fnl.13.29
Bertoni C. Therapy development for neuromuscular diseases: translating hope into promise. Future Neurol. 2013 Jul 01;8(4). doi: 10.2217/fnl.13.29. PMID: 24273459; PMCID: PMC3834955.
Copy Download .nbib Format: NLM
TDP-43 stabilizes G3BP1 mRNA: relevance to amyotrophic lateral sclerosis/frontotemporal dementia.

Brain : a journal of neurology

Sidibé H, Khalfallah Y, Xiao S, Gómez NB, Fakim H, Tank EMH, Di Tomasso G, Bareke E, Aulas A, McKeever PM, Melamed Z, Destroimaisons L, Deshaies JE, Zinman L, Parker JA, Legault P, Tétreault M, Barmada SJ, Robertson J, Vande Velde C.
PMID: 34115105
Brain. 2021 Dec 16;144(11):3461-3476. doi: 10.1093/brain/awab217.

TDP-43 nuclear depletion and concurrent cytoplasmic accumulation in vulnerable neurons is a hallmark feature of progressive neurodegenerative proteinopathies such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Cellular stress signalling and stress granule dynamics are now recognized to...

Cite
Sidibé H, Khalfallah Y, Xiao S, et al. TDP-43 stabilizes G3BP1 mRNA: relevance to amyotrophic lateral sclerosis/frontotemporal dementia. Brain. 2021;144(11):3461-3476doi: 10.1093/brain/awab217.
Sidibé, H., Khalfallah, Y., Xiao, S., Gómez, N. B., Fakim, H., Tank, E. M. H., Di Tomasso, G., Bareke, E., Aulas, A., McKeever, P. M., Melamed, Z., Destroimaisons, L., Deshaies, J. E., Zinman, L., Parker, J. A., Legault, P., Tétreault, M., Barmada, S. J., Robertson, J., & Vande Velde, C. (2021). TDP-43 stabilizes G3BP1 mRNA: relevance to amyotrophic lateral sclerosis/frontotemporal dementia. Brain : a journal of neurology, 144(11), 3461-3476. https://doi.org/10.1093/brain/awab217
Sidibé, Hadjara, et al. "TDP-43 stabilizes G3BP1 mRNA: relevance to amyotrophic lateral sclerosis/frontotemporal dementia." Brain : a journal of neurology vol. 144,11 (2021): 3461-3476. doi: https://doi.org/10.1093/brain/awab217
Sidibé H, Khalfallah Y, Xiao S, Gómez NB, Fakim H, Tank EMH, Di Tomasso G, Bareke E, Aulas A, McKeever PM, Melamed Z, Destroimaisons L, Deshaies JE, Zinman L, Parker JA, Legault P, Tétreault M, Barmada SJ, Robertson J, Vande Velde C. TDP-43 stabilizes G3BP1 mRNA: relevance to amyotrophic lateral sclerosis/frontotemporal dementia. Brain. 2021 Dec 16;144(11):3461-3476. doi: 10.1093/brain/awab217. PMID: 34115105; PMCID: PMC8677511.
Copy Download .nbib Format: NLM
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.

The Lancet. Neurology

Uccelli A, Laroni A, Ali R, Battaglia MA, Blinkenberg M, Brundin L, Clanet M, Fernandez O, Marriot J, Muraro P, Nabavi SM, Oliveri RS, Radue E, Ramo Tello C, Schiavetti I, Sellner J, Sorensen PS, Sormani MP, Wuerfel JT, Freedman MS.
PMID: 34687636
Lancet Neurol. 2021 Nov;20(11):917-929. doi: 10.1016/S1474-4422(21)00301-X.

BACKGROUND: Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, have been proposed as a promising therapeutic option for people with multiple sclerosis on the basis of their immunomodulatory and neuroprotective properties. The MEsenchymal StEm cells for Multiple...

Cite
Uccelli A, Laroni A, Ali R, et al. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurol. 2021;20(11):917-929doi: 10.1016/S1474-4422(21)00301-X.
Uccelli, A., Laroni, A., Ali, R., Battaglia, M. A., Blinkenberg, M., Brundin, L., Clanet, M., Fernandez, O., Marriot, J., Muraro, P., Nabavi, S. M., Oliveri, R. S., Radue, E., Ramo Tello, C., Schiavetti, I., Sellner, J., Sorensen, P. S., Sormani, M. P., Wuerfel, J. T., Freedman, M. S. (2021). Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. The Lancet. Neurology, 20(11), 917-929. https://doi.org/10.1016/S1474-4422(21)00301-X
Uccelli, Antonio, et al. "Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial." The Lancet. Neurology vol. 20,11 (2021): 917-929. doi: https://doi.org/10.1016/S1474-4422(21)00301-X
Uccelli A, Laroni A, Ali R, Battaglia MA, Blinkenberg M, Brundin L, Clanet M, Fernandez O, Marriot J, Muraro P, Nabavi SM, Oliveri RS, Radue E, Ramo Tello C, Schiavetti I, Sellner J, Sorensen PS, Sormani MP, Wuerfel JT, Freedman MS. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurol. 2021 Nov;20(11):917-929. doi: 10.1016/S1474-4422(21)00301-X. PMID: 34687636.
Copy Download .nbib Format: NLM
Development of clinical practice guidelines for allied health and nursing assessment and management of Duchenne muscular dystrophy.

Disability and rehabilitation

Davidson ZE, Bray P, Rose K, Rodrigues MJ, Corben L, North KN, Ryan MM, Burns J.
PMID: 34165385
Disabil Rehabil. 2021 Jun 24;1-18. doi: 10.1080/09638288.2021.1936221. Epub 2021 Jun 24.

PURPOSE: To provide evidence-based guidance specific to allied health and nursing practice for the assessment and management of individuals with Duchenne muscular dystrophy (DMD).MATERIALS AND METHODS: Thirteen key focus areas were identified in consultation with health professionals and consumer...

Cite
Davidson ZE, Bray P, Rose K, et al. Development of clinical practice guidelines for allied health and nursing assessment and management of Duchenne muscular dystrophy. Disabil Rehabil. 2021;1-18doi: 10.1080/09638288.2021.1936221.
Davidson, Z. E., Bray, P., Rose, K., Rodrigues, M. J., Corben, L., North, K. N., Ryan, M. M., Burns, J. (2021). Development of clinical practice guidelines for allied health and nursing assessment and management of Duchenne muscular dystrophy. Disability and rehabilitation, 1-18. https://doi.org/10.1080/09638288.2021.1936221
Davidson, Z E, et al. "Development of clinical practice guidelines for allied health and nursing assessment and management of Duchenne muscular dystrophy." Disability and rehabilitation vol. (2021): 1-18. doi: https://doi.org/10.1080/09638288.2021.1936221
Davidson ZE, Bray P, Rose K, Rodrigues MJ, Corben L, North KN, Ryan MM, Burns J. Development of clinical practice guidelines for allied health and nursing assessment and management of Duchenne muscular dystrophy. Disabil Rehabil. 2021 Jun 24;1-18. doi: 10.1080/09638288.2021.1936221. Epub 2021 Jun 24. PMID: 34165385.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 27 entries